Mark James Levis, MD, PhD, program leader of Hematologic Malignancies and Bone Marrow Transplant Program at Sidney Kimmel Comprehensive Cancer Center, and professor of oncology, Johns Hopkins Medicine, discusses an analysis of gilteritinib (Xospata) in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML) harboring other common co-mutations or a high FLT3-internal tandem duplication (ITD) allelic ratio.
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]
![What can dads do for breastfeeding {family bonding]](https://i.ytimg.com/vi/dFf47XUIqys/mqdefault.jpg)
